GlassScriptPhysician profile
Aaron Alan Cochran
NPI 1164710307
$630.33
in general payments reported to CMS, 2019-2025
13 companies · $349 in 2025
The $349 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13.17 · 2020: $19.85 · 2021: $182 · 2022: $67.21 · 2025: $349.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $301 · Education: $47.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $301.33 |
| Education | $47.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $175.48 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $122.54 | 2021-2025 | Ultomiris |
| Amgen INC. | $63.26 | 2025 | Uplizna |
| Pfizer INC. | $49.33 | 2025 | |
| Argenx US, INC. | $34.89 | 2025 | Vyvgart Hytrulo |
| Takeda Pharmaceuticals U.S.A., INC. | $32.97 | 2025 | Hyqvia |
| Axsome Therapeutics, INC. | $32.95 | 2025 | Symbravo |
| Ucb, INC. | $27.15 | 2025 | Zilbrysq |
| Biogen, INC. | $22.96 | 2025 | Tysabri, Vumerity |
| Celgene Corporation | $19.85 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $18.42 | 2025 | Austedo Xr |
| Impel Pharmaceuticals LLC | $17.36 | 2025 | Trudhesa |
| Emd Serono, INC. | $13.17 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aaron Cochran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.